Latest Headlines from Nourish | The Nourish Mission

Ibogaine funding moves forward for PTSD studies

What's happened

Health Secretary Kennedy has announced up to $4.9 million to prepare U.S. studies of ibogaine for PTSD in veterans, with safety concerns and regulatory constraints noted; the program aims to accelerate clinical trials while exploring broader uses for addiction.

What's behind the headline?

Brief

  • The announcement frames ibogaine as a path to faster PTSD treatment but is cautious about safety. The program shifts from pure exploratory research to groundwork for manufacturing, dosing, and trial design.
  • Expect ongoing debates about safety, ethics, and regulatory hurdles; the policy signals may speed up approvals if safety data is favorable.

Forecast

  • If safety concerns are adequately addressed, the research could pave the way for first-in-human trials within 12-24 months and potential approvals for PTSD or substance-use indications in the longer term.

Reader relevance

  • Veterans and families may feel both optimism and caution as trials approach. Regulators will weigh risks against potential benefits as funding ramps up.

How we got here

The initiative builds on past psychedelic research and a 2026 push by officials including President Trump to accelerate psychedelic science. Ibogaine is illegal in the U.S. but has a history of use overseas; Kennedy says groundwork will enable safe, rapid trials.

Our analysis

Washington Post (Dan Diamond) and Washington Post (Meryl Kornfield) report up to $4.9 million in ARPA-H funding for ibogaine studies; AP News provides context on safety risks and Beond Inc. involvement.

Go deeper

  • What are the safety safeguards for ibogaine trials?
  • When could human trials begin if the data are favorable?
  • How does this funding compare with other psychedelic programs?

More on these topics


Latest Headlines from Nourish | The Nourish Mission